entri
two
dengu
viru
denv
serotyp
vero
cell
analys
use
biochem
inhibitor
domin
neg
mutant
cellular
protein
involv
endocyt
pathway
fluoresc
microscopi
infect
determin
treatment
dansylcadaverin
chlorpromazin
overexpress
domin
neg
form
protein
clathrinmedi
endocytosi
product
intern
vero
cell
demonstr
wherea
infecti
entri
cell
system
independ
clathrin
treatment
inhibitor
nystatin
methylbcyclodextrin
well
transfect
vero
cell
domin
neg
effect
viru
infect
also
shown
use
mutant
inhibitor
dynasor
dynamin
requir
entri
consequ
infecti
entri
vero
cell
occur
nonclass
endocyt
pathway
independ
clathrin
caveola
lipid
raft
depend
dynamin
contrast
entri
cell
clathrindepend
previous
report
hela
cell
result
conclus
show
first
time
differenti
mode
infect
entri
common
host
cell
vero
cell
well
altern
entri
pathway
given
serotyp
differ
type
cell
dengu
viru
denv
envelop
posit
singlestrand
rna
viru
belong
genu
flaviviru
famili
flavivirida
respons
preval
arthropodeborn
viral
infect
human
four
antigen
relat
serotyp
cocircul
tropic
subtrop
region
around
world
vector
mosquito
aed
aegypti
albopictu
vertebr
host
denv
human
infect
manifest
either
benign
selflimit
febril
ill
call
dengu
fever
df
sever
potenti
fatal
diseas
name
dengu
haemorrhag
feverdengu
shock
syndrom
dhfdss
gubler
primari
infect
induc
protect
immun
infect
serotyp
secondari
infect
serotyp
appear
one
risk
factor
develop
dhfdss
immunopatholog
process
antibodydepend
enhanc
ade
klik
et
al
rothman
failur
maintain
programm
control
mosquito
vector
caus
global
reemerg
infect
turn
denv
public
health
problem
current
estim
viru
endem
countri
produc
million
infect
year
gubler
despit
increas
incid
denv
human
pathogen
antivir
agent
vaccin
treatment
prevent
littl
known
denv
multipl
cycl
particular
initi
step
lead
denv
entri
host
cell
primari
infect
present
poorli
understood
event
involv
viru
entri
compris
virion
bind
cell
surfac
receptor
follow
intern
cytoplasm
envelop
e
glycoprotein
identifi
denv
protein
involv
attach
intern
repres
key
determin
infect
contrast
ident
cellular
receptor
interact
e
glycoprotein
present
controversi
sever
recent
report
implic
long
list
receptor
candid
molecul
includ
wide
divers
protein
heparan
sulfat
proteoglycan
review
acosta
et
al
probabl
reason
complex
may
abil
denv
replic
wide
spectrum
cell
diamond
et
al
suggest
possibl
diverg
receptor
accord
type
host
cell
plausibl
mechan
emerg
conflict
data
multistep
process
consist
sequenti
interact
e
least
two
target
molecul
abund
attach
receptor
concentr
viru
particl
cell
surfac
facilit
subsequ
interact
high
affin
second
receptor
protein
natur
mediat
viru
intern
accord
cell
type
heparan
sulfat
lectin
dcsign
propos
put
primari
receptor
del
angel
lozach
et
al
upon
receptor
bind
envelop
virus
exploit
two
main
pathway
intern
nucleocapsid
cytoplasm
membran
fusion
cell
surfac
phindepend
within
intracellular
vesicl
endocytosi
phdepend
earlier
studi
show
electron
microscopi
observ
penetr
directli
cytoplasm
human
monocyt
mosquito
bhk
cell
fusion
virion
envelop
plasma
membran
physiolog
ph
hase
et
al
lim
ng
wherea
format
low
phinduc
syncytia
infect
cell
also
publish
randolph
stollar
recent
report
provid
evid
uptak
virion
hela
mosquito
cell
occur
receptormedi
endocytosi
depend
intravesicular
low
ph
membran
fusion
activ
krishnan
et
al
van
der
schaar
et
al
acosta
et
al
mosso
et
al
similarli
observ
member
flaviviru
mizutani
et
al
nawa
et
al
chu
ng
chu
et
al
despit
gener
consensu
ph
requir
viral
fusion
inform
precis
intracellular
pathway
denv
intern
scanti
controversi
product
infect
hela
mosquito
cell
function
entri
clathrindepend
krishnan
et
al
acosta
et
al
mosso
et
al
van
der
schaar
et
al
common
wellknown
mode
endocytosi
contrast
result
report
role
membran
cholesterol
entri
divers
cellular
system
human
monocyt
reyesdel
vall
et
al
mous
neuroblastoma
cell
lee
et
al
mosquito
cell
acosta
et
al
mosso
et
al
umashankar
et
al
addit
report
address
function
entri
mechan
util
serotyp
clinic
characterist
associ
distinct
serotyp
precis
defin
divers
epidemiolog
studi
report
caus
sever
diseas
vaughn
et
al
nisalak
et
al
balmaseda
et
al
thu
knowledg
viruscel
interact
lead
success
infect
differ
denv
serotyp
may
help
understand
vari
vivo
pathogen
profil
analys
compar
infecti
entri
serotyp
vero
cell
systemat
util
varieti
biochem
molecular
inhibitor
result
conclus
demonstr
altern
entri
rout
taken
differ
denv
serotyp
within
host
cell
also
serotyp
differ
cell
system
defin
accur
condit
viral
intern
assay
requir
monitor
denv
entri
differ
treatment
determin
first
kinet
rate
viru
penetr
vero
cell
measur
product
intern
viru
particl
end
cell
infect
incub
h
allow
viru
attach
cell
wash
pb
shift
permit
intern
bound
particl
variou
time
shift
seri
infect
cultur
treat
proteinas
k
remov
adsorb
viru
wherea
intern
viru
remain
protect
insid
cell
inactiv
enzym
suspens
infect
cell
plate
vero
cell
monolay
quantifi
infecti
intern
particl
plaqu
format
anoth
seri
cultur
treat
pb
time
temperatur
shift
similar
infecti
centr
assay
perform
quantifi
total
cellassoci
viru
membranebound
intern
virion
percentag
pfu
resist
proteinas
k
treatment
comparison
control
pb
treatment
calcul
time
point
shown
fig
begin
temperatur
shift
particl
detach
cell
proteinas
k
time
incub
increas
viru
becam
rapidli
resist
min
incub
viru
resist
proteinas
k
treatment
comparison
control
treatment
indic
success
intern
infecti
virion
similar
profil
time
amount
intern
viru
vero
cell
determin
infecti
centr
assay
obtain
data
shown
inhibitor
endocyt
pathway
test
lack
cytotox
cell
treat
short
time
period
certain
cultur
condit
see
experiment
procedur
particular
cell
treat
inhibitor
maintain
fulli
viabl
incub
consequ
kinet
rate
viru
intern
test
cell
nonpreincub
h
condit
previous
chosen
separ
adsorpt
intern
process
vero
cell
infect
denv
immedi
incub
differ
time
amount
intern
viru
particl
determin
proteinas
k
treatment
infecti
centr
assay
describ
curv
viru
intern
assay
condit
compar
obtain
h
preincub
fig
slight
differ
number
infecti
intern
viru
initi
detect
probabl
due
lack
synchron
penetr
preadsorb
virion
min
amount
proteinas
kresist
viru
penetr
cell
similar
assay
thu
effect
inhibitor
viru
intern
measur
proteas
treatment
infecti
centr
assay
h
denv
infect
test
role
low
ph
entri
vero
cell
evalu
effect
ammonium
chlorid
lysosomotrop
weak
base
immedi
rais
ph
intracellular
acid
vesicl
concanamycin
select
inhibitor
vacuolar
proton
atpas
mizzen
et
al
castilla
et
al
guinea
carrasco
treatment
vero
cell
ammonium
chlorid
concanamycin
infect
first
hour
infect
significantli
reduc
amount
intern
viru
serotyp
maximum
effect
concentr
mm
nm
respect
fig
low
ph
requir
also
assess
inhibit
viral
yield
fig
viral
antigen
express
detect
immunofluoresc
assay
fig
howev
inhibitori
effect
viru
multipl
detect
ammonium
chlorid
ad
h
infect
confirm
compound
effect
block
earli
event
viru
entri
process
fig
furthermor
virucid
effect
ammonium
chlorid
detect
viru
preincub
compound
infect
fig
neither
viru
adsorpt
affect
fig
similarli
lack
effect
virion
inactiv
adsorpt
detect
concanamycin
data
shown
ensur
drug
concentr
use
effect
increas
ph
intracellular
vesicl
vero
cell
perform
acridin
orang
stain
untreat
cell
show
typic
cytoplasmat
orang
fluoresc
acid
compart
cell
treat
ammonium
chlorid
concanamycin
infect
h
intern
presenc
drug
extracellular
viru
inactiv
proteinas
k
cell
pellet
plate
onto
vero
cell
determin
intern
viru
infecti
centr
assay
result
express
percentag
intern
viru
respect
control
without
drug
treatment
point
show
mean
sd
two
independ
experi
b
cell
treat
mm
ammonium
chlorid
infect
left
untreat
control
h
pi
immunostain
carri
use
mous
anti
glycoprotein
antibodi
fitclabel
antimous
igg
wherea
cell
treat
ammonium
chlorid
concanamycin
exhibit
fluoresc
pattern
fig
thu
conclud
requir
acid
intracellular
ph
penetr
vero
cell
indic
viru
entri
occur
low
phdepend
endocyt
rout
clathrinmedi
endocytosi
classic
low
phdepend
pathway
use
differ
virus
enter
cell
sieczkarski
whittak
marsh
heleniu
addit
involv
clathrin
entri
mosquito
cell
acosta
et
al
mosso
et
al
human
hela
cell
krishnan
et
al
cell
van
der
schaar
et
al
recent
report
address
involv
clathrinmedi
pathway
entri
vero
cell
analys
effect
viru
infect
chlorpromazin
dansylcadaverin
two
pharmacolog
inhibitor
pathway
chu
et
al
leppert
et
al
zheng
et
al
dosedepend
inhibit
intern
fig
product
h
postinfect
pi
fig
obtain
vero
cell
treat
compound
first
hour
infect
maximum
reduct
viru
intern
control
valu
concentr
mm
chlorpromazin
mm
dansylcadaverin
respect
surprisingli
neither
chlorpromazin
dansylcadaverin
treatment
produc
inhibitori
effect
infect
fig
b
contrari
signific
increas
number
intern
virion
pfu
releas
infect
vero
cell
detect
clathrindepend
endocytosi
block
valu
higher
control
fig
b
intern
tritclabel
transferrin
ligand
known
enter
cell
clathrinmedi
endocytosi
use
function
control
assay
assess
action
inhibitor
effect
exert
receptormedi
endocytosi
clathrinco
pit
control
cell
dot
fluoresc
pattern
insid
cell
cytoplasm
observ
cultur
treat
chlorpromazin
exhibit
widespread
fluoresc
cell
surfac
indic
transferrin
uptak
effici
arrest
fig
similar
stain
pattern
observ
treatment
dansylcadaverin
data
shown
consequ
result
obtain
biochem
inhibitor
suggest
entri
vero
cell
occur
clathrindepend
endocytosi
would
use
anoth
endocyt
rout
assess
differenti
role
clathrinmedi
endocytosi
entri
serotyp
vero
cell
specif
molecular
inhibitor
next
assay
domin
neg
mutant
clathrin
coatassoci
cellular
protein
name
specif
interfer
clathrinco
pit
assembl
plasma
membran
without
affect
clathrin
independ
endocyt
pathway
benmerah
et
al
vero
cell
transfect
gfptag
version
domin
neg
mutant
control
construct
affect
clathrinmedi
uptak
benmerah
et
al
twentyfour
hour
post
transfect
cell
infect
h
process
detect
gfp
express
intern
viral
antigen
indirect
immunofluoresc
stain
vero
cell
transfect
control
construct
virion
intern
endocyt
vesicl
exhibit
speckl
viru
antigen
stain
within
cytoplasm
fig
similar
pattern
observ
mutant
transfect
cell
infect
indic
capabl
enter
vero
cell
clathrinmedi
uptak
block
fig
contrast
slight
dispers
red
fluoresc
cell
surfac
demonstr
blockad
viru
entri
detect
transfect
cell
provid
addit
strong
evid
intern
vero
cell
occur
fig
entri
vero
cell
requir
clathrinmedi
endocytosi
entri
clathrinindepend
cell
treat
chlorpromazin
dansylcadaverin
infect
h
intern
presenc
drug
monolay
treat
proteinas
k
cell
pellet
plate
onto
vero
cell
determin
intern
viru
infecti
centr
assay
b
cell
treat
infect
viru
yield
quantifi
h
pi
result
express
percentag
viru
multipl
respect
control
without
drug
treatment
c
cell
treat
mm
chlorpromazin
left
untreat
control
incub
tritclabel
transferrin
cell
transient
transfect
construct
infect
incub
tritclabel
transferrin
h
cell
fix
intern
viral
particl
visual
immunofluoresc
stain
use
mous
anti
glycoprotein
antibodi
tritclabel
antimous
igg
e
cell
transient
transfect
infect
h
cell
fix
viral
antigen
express
visual
immunofluoresc
stain
use
mous
anti
glycoprotein
antibodi
tritclabel
antimous
igg
via
clathrindepend
pathway
function
construct
prove
assay
transferrin
incorpor
transfect
cell
expect
express
domin
neg
protein
control
inhibit
transferrin
uptak
fig
examin
effect
overexpress
product
infect
transfect
cell
allow
infect
h
proceed
cell
fixat
stain
express
domin
neg
mutant
significantli
affect
infect
indic
similar
signal
merg
imag
domin
control
transfect
cell
fig
data
h
infect
quantifi
score
cell
posit
viral
antigen
cell
compar
level
transgen
express
cell
repres
transgeneexpress
cell
transfect
cell
respect
fig
experiment
procedur
perform
infect
abil
vero
cell
product
infect
serotyp
block
clathrin
depend
endocytosi
interrupt
domin
neg
mutant
transfect
reduc
percentag
cell
transfect
cell
transfect
cell
fig
f
conclus
data
confirm
capabl
enter
caus
product
infect
vero
cell
lack
function
clathrinmedi
endocytosi
wherea
infect
vero
cell
requir
endocyt
pathway
better
character
clathrinindepend
endocyt
rout
use
enter
vero
cell
next
approach
analys
step
entri
process
requir
integr
lipid
raft
andor
caveola
lipid
raft
cholesteroland
sphingolipidrich
membran
microdomain
use
certain
virus
toxin
enter
cell
nichol
lippincottschwartz
kirkham
parton
caveola
vesicl
aris
special
lipid
raft
associ
protein
caveolin
pelkman
raftcaveolaedepend
pathway
highli
sensit
cholesteroldeplet
agent
disrupt
lipid
bilay
structur
wherea
clathrindepend
endocytosi
affect
high
dose
anderson
et
al
damm
et
al
determin
step
entri
traffick
acid
vesicl
sensit
perturb
lipid
raft
evalu
effect
viru
infect
nystatin
methylbcyclodextrin
sterolbind
drug
sequest
cholesterol
extract
case
methylbcyclodextrin
complex
format
membran
case
nystatin
block
lipid
raftdepend
entri
pathway
ilangumaran
hoessli
anderson
et
al
pelkman
et
al
sinc
class
compound
also
modifi
lipid
bilay
viru
envelop
lead
viru
inactiv
first
analys
virucid
effect
nystatin
methylbcyclodextrin
incub
suspens
differ
concentr
compound
h
sampl
dilut
remain
infect
titrat
pfu
vero
cell
sampl
dilut
effect
reduc
drug
concentr
incub
cell
least
assess
titr
reduct
due
cellfre
virion
inactiv
seen
fig
methylbcyclodextrin
exert
dosedepend
inactiv
activ
virion
probabl
consequ
envelop
alter
interact
cholesterol
nystatin
exert
inactiv
effect
denv
someth
lower
methylbcyclodextrin
data
fig
entri
vero
cell
independ
caveolaelipidraft
depend
dynamin
suspens
incub
variou
concentr
methylbcyclodextrin
h
remain
infect
determin
b
vero
cell
pretreat
nystatin
methylbcyclodextrin
monolay
wash
pb
infect
cultur
medium
without
serum
h
intern
cultur
treat
proteinas
k
cell
pellet
plate
onto
vero
cell
determin
intern
viru
infecti
centr
assay
result
express
percentag
intern
viru
respect
control
without
drug
treatment
c
cell
untreat
control
treat
mm
nystatin
mm
methylbcyclodextrin
cultur
incub
fitclabel
cholera
toxin
cell
transient
transfect
construct
wt
gfp
dn
infect
h
infect
cultur
fix
immunofluoresc
stain
perform
e
quantif
sampl
shown
transfect
cell
similar
level
gfp
express
screen
cell
posit
viral
antigen
score
f
vero
cell
treat
dynasor
infect
presenc
drug
process
b
g
cell
transient
transfect
construct
gfpdyn
ii
wt
gfpdyn
ii
infect
h
infect
cultur
fix
immunofluoresc
stain
perform
shown
base
result
treatment
condit
test
effect
drug
denv
infect
chosen
affect
lipid
raft
organ
cell
membran
without
direct
contact
drug
virion
thu
vero
cell
preincub
increas
concentr
nystatin
methylbcyclodextrin
monolay
extens
wash
infect
probe
neg
control
absenc
compound
pretreat
drug
neither
affect
intern
fig
product
vero
cell
h
pi
data
shown
expect
viru
use
clathrinmedi
endocytosi
fig
intern
affect
inhibitor
test
concentr
fig
posit
control
effect
cell
treatment
drug
lipid
raftcaveola
pathway
perform
assay
entri
fitclabel
cholera
toxin
marker
intern
rout
similar
treatment
use
viru
entri
assay
untreat
cell
show
clear
dot
perinuclear
cytoplasm
fluoresc
due
accumul
toxin
endoplasm
reticulum
golgi
apparatu
wherea
treatment
nystatin
methylbcyclodextrin
result
diffus
green
fluoresc
pattern
indic
impair
toxin
incorpor
fig
blockad
cholera
toxin
entri
show
function
lipid
raft
destroy
drug
treatment
lack
inhibitori
effect
infect
indic
drug
concentr
high
affect
endocyt
pathway
like
clathrinmedi
endocytosi
consequ
valid
conclud
experi
pharmacolog
inhibitor
entri
independ
lipid
raft
caveola
address
lack
caveolaemedi
endocytosi
infect
vero
cell
complementari
manner
impact
express
domin
neg
mutant
major
structur
protein
caveola
next
studi
fusion
gfp
ntermin
domain
sequenc
inhibit
function
protein
act
domin
neg
mutant
name
dn
gfp
fusion
ctermin
end
affect
protein
wt
pelkman
et
al
recent
new
form
domin
neg
mutant
name
gener
point
mutat
prevent
phosphoryl
coyn
bergelson
vero
cell
transfect
wildtyp
mutant
form
h
posttransfect
cell
infect
h
infect
cell
fix
analys
gfp
express
quantifi
transfect
cell
immunofluoresc
stain
antigen
detect
infect
cell
shown
fig
express
domin
neg
mutant
caveolin
dn
effect
infect
cell
percentag
infect
transgeneexpress
cell
determin
score
cell
express
viral
antigen
similar
cultur
transfect
three
construct
fig
therebi
strengthen
conclus
entri
independ
caveolaemedi
endocytosi
expect
domin
neg
mutant
caveolin
affect
entri
vero
cell
fig
b
altogeth
result
denot
rout
infect
entri
vero
cell
endocyt
pathway
independ
clathrin
lipid
raftscaveola
recent
year
certain
virus
report
use
similar
rout
fulli
character
sieczkarski
whittak
quirin
et
al
rojek
et
al
particular
particip
dynamin
clearli
elucid
nonclathrin
noncaveolar
pathway
conner
schmid
cao
et
al
dynamin
gtpase
essenti
pinch
vesicl
clathrinand
caveolaedepend
endocytosi
probe
dynamin
involv
entri
vero
cell
effect
dynasor
recent
develop
dynamin
inhibitor
macia
et
al
evalu
although
infect
vero
cell
clathrinor
caveolindepend
treatment
dynasor
viru
infect
significantli
reduc
intern
fig
well
viru
product
h
pi
data
shown
posit
control
determin
intern
inhibit
dynasor
treatment
fig
confirm
particip
dynamin
entri
vero
cell
gfptag
version
wildtyp
form
dynamin
ii
gfpdyn
ii
wt
domin
neg
mutant
gfpdyn
ii
use
damk
et
al
oh
et
al
sauvonnet
et
al
vero
cell
transfect
construct
h
transfect
cell
infect
h
pi
cultur
process
immunofluoresc
cell
express
similar
level
gfptag
wildtyp
mutant
form
dynamin
select
stain
viral
antigen
score
seen
fig
multipl
affect
cell
express
domin
neg
mutant
percentag
infect
gfpdyn
ii
wt
gfpdyn
ii
transfect
cell
respect
fig
express
mutant
dynamin
also
significantli
reduc
infect
cell
line
gfpdyn
ii
wt
transfect
cell
percentag
infect
wherea
cell
transfect
gfpdyn
ii
cell
infect
fig
thu
conclud
infect
entri
serotyp
vero
cell
depend
dynamin
function
nonclathrin
noncaveolar
endocyt
pathway
intern
vero
cell
character
investig
possibl
involv
cellular
cytoskeleton
process
address
role
actin
network
entri
analys
effect
two
drug
cytochalasin
latrunculin
disturb
microfila
integr
actin
depolimer
rojek
et
al
third
compound
jasplakinolid
act
induc
rigid
stabil
actin
polym
blockad
microfila
dynam
rojek
et
al
inhibit
observ
multipl
treatment
compound
fig
lack
effect
actindisturb
agent
entri
also
assess
intern
assay
shown
fig
cytochalasin
although
effect
compound
destroy
typic
pattern
actin
microfila
bundl
thin
fiber
observ
stain
fitclabel
phalloidin
fig
data
differ
type
inhibitor
allow
conclud
structur
dynam
actin
microfila
involv
endocyt
entri
vero
cell
addit
result
repres
first
evid
toward
probabl
exclus
macropinocytosi
phagocytosi
possibl
mechan
intern
although
neither
macropinocytosi
phagocytosi
frequent
involv
viru
entri
report
altern
access
virus
certain
cell
et
al
clement
et
al
amstutz
et
al
two
wellknown
endocyt
rout
cell
entri
independ
clathrin
caveola
strictli
depend
factin
network
swanson
watt
intend
obtain
evid
role
macropinocytosi
use
amilorid
inhibitor
nah
exchang
plasma
membran
swanson
watt
compound
exert
virucid
activ
inactiv
cellfre
virion
data
shown
function
microtubul
cytoskeleton
infect
vero
cell
studi
cell
pretreat
nocodazol
colchicin
inhibitor
microtubul
assembl
bind
tubulin
hamel
effect
compound
microtubul
organ
verifi
use
monoclon
antibodi
tubulin
stain
pattern
observ
network
tubul
radiat
perinuclear
region
cell
peripheri
transform
treatment
mm
nocodazol
fig
mm
colchicin
shown
arrang
condens
amorph
aggreg
cytoplasm
destabil
microtubul
network
nocodazol
colchicin
treatment
viru
entri
caus
signific
reduct
viru
product
fig
well
viru
intern
fig
suggest
requir
structur
integr
microtubul
network
effici
entri
vero
cell
compar
rout
entri
type
mammalian
cell
differ
vero
infect
human
cell
line
presenc
pharmacolog
inhibitor
endocytosi
also
assay
treatment
cell
ammonium
chlorid
chlorpromazin
dansylcadaverin
nystatin
perform
condit
incub
time
drug
concentr
previous
describ
vero
cell
assay
rang
concentr
suffici
induc
essenti
effect
endocyt
pathway
cell
comparison
vero
cell
determin
correspond
stain
marker
fig
drug
treatment
cell
infect
incub
h
supernat
titrat
plaqu
format
vero
cell
dosedepend
signific
reduct
infect
detect
cell
endosom
ph
increas
ammonium
chlorid
pretreat
indic
low
phdepend
endocyt
rout
entri
also
use
mammalian
cell
line
fig
similar
level
dosedepend
inhibit
infect
determin
cell
treat
inhibitor
clathrinmedi
endocytosi
chlorpromazin
dansylcadaverin
fig
c
accordingli
lipid
raftscaveola
requir
infect
cell
sinc
inhibitori
effect
detect
nystatin
treatment
fig
result
indic
entri
cell
depend
clathrinmedi
endocytosi
consequ
differ
pathway
follow
viral
serotyp
vero
cell
shown
fig
studi
intern
pathway
two
denv
serotyp
report
clearli
show
complex
mode
entri
viral
pathogen
vertebr
host
cell
result
conclus
show
first
time
differenti
mode
infect
entri
serotyp
common
host
cell
vero
cell
well
altern
entri
pathway
given
serotyp
differ
type
cell
analysi
effect
biochem
molecular
inhibitor
demonstr
util
clathrinmedi
pathway
endocytosi
wherea
clathrinco
vesicl
requir
entri
virion
vero
cell
addit
infect
assay
presenc
entri
inhibitor
quantit
confirm
result
intern
assay
show
concomit
level
viru
yield
viral
antigen
express
cell
propos
rout
entri
interestingli
consist
signif
increas
yield
observ
infect
perform
presenc
two
inhibitor
clathrinmedi
endocytosi
chlorpromazin
dansylcadaverin
one
possibl
clathrin
pathway
would
noninfect
rout
entri
vero
cell
consequ
block
enhanc
util
virion
infect
nonclathrin
pathway
lead
higher
product
infecti
viru
research
requir
ascertain
hypothesi
one
explain
result
shown
fig
b
comparison
recent
shown
papillomavirus
could
intern
without
induc
product
infect
selinka
et
al
concomitantli
inhibit
clathrinand
caveolaemedi
endocytosi
led
increas
human
papillomaviru
infect
propos
altern
endocyt
mechan
spoden
et
al
therefor
increas
infect
cell
disturb
clathrin
endocytosi
may
repres
addit
support
usag
nonclass
rout
action
differ
agent
perturb
major
clathrinindepend
endocyt
process
infect
vero
cell
suggest
neither
caveola
lipid
raft
appear
involv
viru
entri
appar
contradict
result
reyesdel
vall
et
al
lee
et
al
report
disrupt
lipid
raft
methylbcyclodextrin
deplet
cholesterol
decreas
infect
human
peripher
blood
monocyt
mous
neuroblastoma
cell
respect
contrast
accord
result
umashankar
et
al
demonstr
effici
membran
fusion
cholesteroldeplet
insect
cell
contrast
result
could
reflect
variat
properti
endocytosi
requir
cholesterol
viru
intern
among
differ
cell
well
differ
treatment
condit
achiev
cholesterol
deplet
time
infect
present
studi
especi
interest
dissect
whether
cholesterol
import
constitu
viru
membran
host
cell
membran
structur
address
question
use
methylbcyclodextrin
treat
separ
either
suspens
vero
cell
prior
viru
infect
experiment
condit
concentr
time
exposur
drug
optim
avoid
gener
perturb
membran
properti
clearli
studi
demonstr
druginduc
releas
cholesterol
virion
membran
correl
dramat
loss
infect
wherea
cholesterol
deplet
cell
membran
affect
subsequ
viru
infect
thu
virucid
activ
cholesterol
deplet
drug
also
report
flavivirus
aizaki
et
al
may
induc
fals
infer
role
cellular
cholesterolrich
microdomain
fusion
infect
fact
abovement
report
reyesdel
vall
et
al
lee
et
al
analys
virucid
activ
methylbcyclodextrin
present
know
presenc
cholesterol
lipid
viral
envelop
acquir
bud
process
affect
virion
infect
interest
futur
studi
analys
stage
viru
multipl
cycl
block
infect
methylbcyclodextrininactiv
denv
virion
also
demonstr
use
mutant
inhibitor
dynasor
entri
depend
dynamin
dynamin
activ
initi
thought
specif
clathrinmedi
endocytosi
damk
et
al
evid
gtpase
function
varieti
endocyt
vesicl
scission
event
independ
clathrin
henley
et
al
gold
et
al
pelkman
et
al
sum
result
demonstr
entri
rout
vero
cell
nonclass
endocyt
pathway
independ
clathrin
caveola
lipid
raft
infecti
entri
dengu
viru
serotyp
depend
dynamin
differ
clathrinmedi
rout
use
cell
cell
system
shown
cell
fig
recent
report
hela
cell
krishnan
et
al
acosta
et
al
mosso
et
al
van
der
schaar
et
al
figur
show
multipl
portal
entri
avail
eukaryot
cell
hijack
virus
indic
use
accord
present
knowledg
four
wellknown
rout
phagocytosi
macropinocytosi
clathrinand
caveolaemedi
endocytosi
wherea
nonclathrinand
noncaveolarmedi
pathway
without
particip
lipid
raft
dynamin
less
character
howev
studi
perform
recent
year
increas
number
virus
involv
nonclass
entri
pathway
includ
influenza
viru
sieczkarski
whittak
lymphocyt
choriomening
viru
quirin
et
al
rojek
et
al
human
immunodefici
viru
vidricair
tremblay
rotaviru
et
al
human
papillomaviru
spoden
et
al
coronavirus
van
hamm
et
al
wang
et
al
case
intern
pathway
need
character
compar
establish
similar
differ
furthermor
use
altern
entri
rout
differ
cell
given
viru
appear
occur
may
provid
advantag
improv
chanc
product
viru
entri
expand
host
cell
rang
infect
may
cell
type
differ
rel
action
abund
endocyt
pathway
discuss
differ
may
effect
prefer
rout
entri
viru
precis
wide
spectrum
cell
tropism
wellknown
properti
denv
may
relat
possibl
shown
exploit
option
rout
intracellular
transport
present
mechanist
basi
differ
clathrindepend
entri
vero
cell
fulli
understood
differ
receptor
usag
may
determin
consequenti
rout
entri
compar
studi
receptor
vero
cell
perform
human
liver
cell
two
differ
protein
laminin
receptor
identifi
specif
receptor
respect
jindadamrongwech
et
al
thepparit
smith
also
higher
satur
infect
found
respect
suksanpaisan
smith
anoth
factor
may
affect
denv
entri
presenc
sugar
molecul
viral
surfac
util
two
potenti
nlink
glycosyl
site
e
determin
limit
number
strain
heterogen
among
circul
viru
popul
remain
uncharacter
bryant
et
al
divers
phenotyp
chang
fusion
activ
tropism
virul
morphogenesi
associ
lack
glycosyl
one
site
variabl
behavior
mosquito
mammalian
cell
guirakhoo
et
al
johnson
et
al
bryant
et
al
mondott
et
al
studi
need
reveal
e
glycosyl
relat
endocyt
via
util
denv
entri
final
bind
serotyp
virion
need
expos
intravesicular
low
ph
function
entri
fig
accord
conform
transit
report
e
glycoprotein
acid
condit
allow
membran
fusion
kuhn
et
al
modi
et
al
stiasni
heinz
nayak
et
al
howev
differ
e
postfus
conform
report
nayak
et
al
interestingli
van
der
schaar
et
al
found
distinct
requir
endocyt
traffick
two
strain
serotyp
fig
endocyt
pathway
util
infect
differ
cell
line
infect
vero
cell
occur
classic
clathrinmedi
dynamindepend
endocytosi
infect
cell
line
take
place
nonclass
endocyt
pathway
independ
clathrin
lipidraft
depend
dynamin
entri
rout
differ
clathrinmedi
pathway
follow
infect
cell
previous
shown
infect
cell
acosta
et
al
mosso
et
al
hela
cell
krishnan
et
al
cell
van
der
schaar
et
al
cell
realtim
imag
strain
particl
fuse
within
late
endosom
wherea
virion
strain
ngc
fuse
earli
endosom
may
reflect
differ
ph
threshold
fusion
hypothesi
must
also
evalu
among
denv
serotyp
van
der
schaar
et
al
also
report
major
particl
fuse
acid
vesicl
within
min
pi
accord
result
show
inhibit
entri
h
infect
phrise
effect
ammonium
chlorid
concanamycin
fig
futur
experi
allow
locat
precis
vesicular
ph
fusion
denv
serotyp
monitor
kinet
low
phdepend
entri
vero
cell
kind
acid
organel
fusion
take
place
understand
denv
entri
cell
extend
understand
entri
mechan
also
help
exploit
new
target
antivir
therapi
blockad
denv
entri
host
cell
interest
antivir
strategi
repres
barrier
suppress
begin
infect
altmey
perera
et
al
particular
studi
antidenv
activ
sulfat
polysaccharid
indic
viru
bind
intern
block
class
compound
differenti
suscept
denv
serotyp
polysulf
observ
suscept
serotyp
wherea
show
weak
inhibit
lin
et
al
talarico
et
al
variat
may
ascrib
differ
viruscel
interact
entri
vero
cell
report
simultan
cocircul
four
denv
serotyp
divers
region
asia
america
make
mandatori
requir
potenti
antivir
agent
reactiv
againtst
serotyp
therefor
elucid
precis
mechan
intern
denv
serotyp
provid
opportun
identifi
adequ
target
develop
effect
therapeut
agent
cell
line
vero
african
green
monkey
kidney
lung
carcinoma
human
cell
grown
eagl
minimum
essenti
medium
mem
gibco
supplement
fetal
bovin
serum
mainten
medium
mm
serum
concentr
reduc
ht
mosquito
cell
line
aed
albopictu
adapt
grow
cultur
medium
leibovitz
supplement
tryptos
phosphat
broth
glutamin
mem
nonessenti
amino
acid
solut
fetal
bovin
serum
stock
strain
hawaii
strain
ngc
prepar
ht
cell
titrat
plaqu
format
vero
cell
antidenv
antibodi
mous
monoclon
antibodi
reactiv
e
glycoprotein
four
dengu
serotyp
purchas
abcam
cambridg
uk
monoclon
antibodi
tubulin
goat
antimous
igg
conjug
fluorescein
isothiocyan
fitc
rhodamin
tritc
fitcphalloidin
fitccholera
toxin
b
subunit
purchas
sigmaaldrich
usa
tritchuman
transferrin
molecular
probe
usa
dansylcadaverin
chlorpromazin
nystatin
methylbcyclodextrin
ammonium
chlorid
concanamycin
dynasor
colchicin
nocodazol
cytochalasin
latrunculin
jasplakinolid
acridin
orang
tetrazolium
bromid
mtt
purchas
sigmaaldrich
usa
vero
cell
infect
multipl
infect
moi
pfu
cell
synchron
infect
h
adsorpt
cell
wash
icecold
pb
cover
mm
incub
differ
time
cell
wash
pb
treat
proteinas
k
mg
ml
invitrogen
min
remov
adsorb
intern
viru
proteinas
k
inactiv
mm
pmsf
pb
bovin
seroalbumin
bsa
cell
wash
pb
bsa
low
speed
centrifug
final
pellet
resuspend
mm
differ
serial
dilut
cell
suspens
plate
onto
vero
cell
monolay
cover
mm
contain
methylcellulos
infecti
centr
count
day
accord
viru
serotyp
determin
rate
viral
intern
parallel
set
cultur
process
condit
except
proteinas
k
replac
pb
time
point
number
plaqu
form
pb
control
consid
determin
kinet
viru
intern
nonsynchron
infect
experiment
procedur
perform
exclud
incub
step
entri
mechan
studi
evalu
effect
inhibitor
differ
endocyt
pathway
time
treatment
rang
concentr
adequ
inhibitor
first
determin
cell
viabil
assay
order
avoid
toxic
effect
monolay
vero
cell
grown
micropl
incub
mm
without
compound
cell
viabil
measur
treatment
use
mtt
assay
describ
previous
talarico
et
al
accord
viabil
data
obtain
shown
treatment
condit
inhibitor
chosen
follow
chlorpromazin
mm
concanamycin
nm
colchicin
mm
nocodazol
mm
cytochalasin
mm
cell
pretreat
h
ammonium
chlorid
mm
methylbcyclodextrin
mm
mm
without
serum
dynasor
mm
cell
pretreat
h
dansylcadaverin
mm
latrunculin
mm
jasplakinolid
mm
min
pretreat
nystatin
mm
mm
without
serum
cell
pretreat
h
pretreat
cell
infect
moi
pfu
cell
presenc
drug
except
nystatin
methylbciclodextrin
pretreat
cultur
intens
wash
pb
infect
case
viru
inocula
remov
h
infect
cultur
wash
pb
incub
mm
without
compound
h
pi
supernat
harvest
determin
extracellular
viru
yield
plaqu
assay
order
quantifi
product
intern
viru
particl
vero
cell
treat
drug
condit
mention
infect
moi
pfu
cell
presenc
absenc
compound
h
cell
wash
pb
treat
proteinas
k
process
abovement
assess
effect
ammonium
chlorid
concanamycin
ph
acid
intracellular
vesicl
vero
cell
treat
compound
h
stain
acridin
orang
mg
ml
mm
without
serum
min
cell
wash
twice
pb
mount
pb
visual
fluoresc
microscop
olympu
egfptag
construct
domin
neg
mutant
control
kindli
provid
dra
c
shayo
ibym
argentina
egfptag
construct
wildtyp
wt
domin
neg
mutant
dn
kindli
provid
dr
j
bergelson
univers
pennsylvania
usa
egfptag
wildtyp
dynamin
ii
gfpdyn
ii
wt
domin
neg
mutant
kindli
provid
dr
mcniven
mayo
clinic
usa
vero
cell
grown
cover
slip
confluenc
transfect
construct
use
lipofectamin
reagent
invitrogen
usa
previous
describ
acosta
et
al
briefli
mg
construct
dilut
ml
optimem
combin
ml
optimem
contain
ml
lipofectamin
min
incub
room
temperatur
dnaliposom
complex
ad
cell
cultur
incub
h
time
medium
replac
mm
cell
incub
h
pi
visual
intern
viral
particl
htransfect
cell
cultur
infect
moi
pfu
cell
h
infect
cell
fix
methanol
min
visual
viral
antigen
product
htransfect
cell
cultur
infect
moi
pfu
cell
h
infect
cultur
fix
describ
methanol
fixat
cell
wash
pb
stain
denv
intern
multipl
monoclon
antibodi
e
glycoprotein
follow
tritclabel
goat
antimous
igg
final
wash
pb
cell
mount
glycerol
solut
contain
octan
dabco
percentag
infect
transgeneexpress
cell
calcul
score
number
cell
posit
viral
antigen
approxim
transfect
cell
compar
level
transgen
express
visual
actin
filament
compoundtr
untreat
vero
cell
wash
pb
fix
paraformaldehyd
permeabil
triton
fitcconjug
phalloidin
use
h
room
temperatur
probe
actin
filament
cell
wash
observ
visual
microtubul
network
compoundtr
untreat
vero
cell
wash
pb
fix
methanol
min
cell
incub
mous
antiatubulin
h
wash
pb
primari
antibodi
recogn
antimous
tritc
antibodi
h
cell
wash
mount
visual
assess
effect
drug
treatment
domin
neg
mutant
express
transferrin
cholera
toxin
uptak
studi
perform
briefli
cell
treat
clorpromazin
dansylcadaverin
cultur
transfect
construct
incub
tritctransferrin
mg
ml
h
cell
wash
pb
remov
unintern
ligand
fix
methanol
min
nystatin
methylbcyclodextrin
treatment
pretreat
cell
cultur
wash
incub
fitccholera
toxin
mg
ml
h
cultur
wash
pb
fix
methanol
describ
cell
visual
fluoresc
microscop
olympu
suspens
contain
pfu
ml
incub
equal
volum
mm
without
differ
concentr
compound
h
sampl
chill
dilut
mm
residu
infect
determin
plaqu
format
address
inhibitori
effect
ammonium
chlorid
concanamycin
viru
adsorpt
vero
cell
pretreat
drug
infect
moi
pfu
cell
presenc
absenc
control
drug
h
adsorpt
cell
wash
cold
pb
remov
unadsorb
viru
cell
disrupt
two
cycl
freez
thaw
amount
infecti
bound
viru
measur
plaqu
format
